Anavex Comments on FDA Plan to Expedite Approval of New Alzheimer’s Drugs

Vancouver, BC — March 18, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today commented on the United States Food and Drug Administration’s (FDA) plan to expedite the approval of new treatments for Alzheimer’s disease.  As reported by the New York Times, drugs in clinical trials would qualify for approval if people with very…